Deprescribing Intervention for Patients With Chronic Kidney Disease
Recruiting · NCT06324045 · Interventional (participants receive a specific treatment) · Lead sponsor: Hamad Medical Corporation
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Chronic Kidney Disease (CKD) is recognized as a leading health problem globally. It is associated with multiple consequences such as cardiovascular diseases, infections, reduced cognitive function, and higher mortality rates. In Qatar, it is estimated that 13% of the population suffers from CKD. Management of CKD is associated with polypharmacy (the use of multiple medications), which burdens the patients and leads to adverse health and economic outcomes. As documented by previous studies, CKD setting is associated with a high medication burden, which leads to non-adherence, reduced quality of life, and other negative sequelae. These consequences can be minimized or averted by implementing a deprescribing program. Deprescribing is defined as the supervised process of intentionally stopping a medication, altering the dose or introducing a safer alternative to improve a person's clinical and quality of life outcomes. Previous deprescribing initiatives in inpatient and outpatient hospital settings were successfully implemented. In general, there are limited deprescribing initiatives in CKD settings. There is a need to provide evidence of the impact of deprescribing programs on improving clinical and economic outcomes in this setting. In Qatar, there is no evidence of the effectiveness of implementing deprescribing programs in clinical settings. Therefore, we have built a team of researchers, clinicians, and stakeholders, and initiated a collaboration with deprescribing experts to fit into the Qatar healthcare system. This project aims to initiate a deprescribing multidisciplinary team and to evaluate the impact of providing such services on the clinical and economic outcomes among CKD patients in Qatar using a randomized controlled trial approach. The findings could have a potential positive impact on the professional practice and patient safety represented by health and economic outcomes.
Who can take part
Inclusion criteria
- Patients who are:
- diagnosed with ESRD receiving hemodialysis treatment or pre-dialysis patients who are followed up at a low clearance clinic.
- receiving treatment at one of the ambulatory kidney centers in Qatar for at least two months.
- able to communicate in Arabic and/or English.
Exclusion criteria
- Unstable or has a psychiatric condition.
- Presents with uncontrolled behaviors or exit-seeking behaviors (i.e., seeking to leave the premises out of confusion, frustration, or anger).
- Critically ill patients, pregnant women, children, mentally ill, dementia, and unconscious patients.
- Patients with limited life expectancy (less than 6 months).
Where it is running
1 location listed.
- Hamad Medical Corporation - Doha, Qatar